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ABSTRACT 
Many potential pitfalls and artefacts have been described in PET imaging that uses F 18 fluorodeoxyglucose (FDG). 
Normal uptake of FDG occurs in many sites of the body and may cause confusion in interpretation particularly in 
oncology imaging. Clinical correlation, awareness of the areas of normal uptake of FDG in the body and knowledge of 
variation in uptake as well as benign processes that are FDG avid are necessary to avoid potential pitfalls in image 
interpretation. In this context, optimum preparation of patients for their scans can be instituted in an attempt to reduce 
the problem. Many of the problems and pitfalls associated with areas of normal uptake of FDG can be solved by using 
PET CT imaging. PET CT imaging has the ability to correctly attribute FDG activity to a structurally normal organ on 
CT. However, the development of combined PET CT scanners also comes with its own specific problems related to the 
combined PET CT technique. These include misregistration artefacts due to respiration and the presence of high density 
substances which may lead to artefactual overestimation of activity if CT data are used for attenuation correction. © 
2006 Biomedical Imaging and Intervention Journal. All rights reserved. 
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INTRODUCTION 
F 18  fluorodeoxyglucose  (FDG)  is  the  radiotracer 
most commonly used for PET imaging. The molecule is 
easiest  to  understand  by  interpreting  it  backwards, 
starting  with  the  molecule  of  glucose.  The  deoxy  part 
implies cleavage of a hydroxyl group from the glucose. 
The attachment of the F 18 tracer to the glucose replaces 
the hydroxyl group.  
In  this  way,  the  FDG  molecule  acts  like  glucose 
during  initial  enzymatic  reactions  within  cells,  but  the 
altered  structure  prevents  further  metabolism.  This 
essentially traps FDG within cells and FDG accumulates 
in most tissues at a rate proportional to glycolysis [1]. 
Malignant  cells  have  increased  glucose  transporter 
proteins on their cell surface as well as enhanced rates of 
glycolysis.  The  enhanced  glycolytic  rate  of  malignant 
cells  facilitates  their  detection  utilizing  PET  FDG 
imaging.  It  is  this  attribute  that  causes  metabolically 
active  tumours  to  appear  ‘hot’  on  PET  scans.  PET 
measures  FDG  retention  per  volume  of  tissue.  Some 
tumours  are  known  to  have  a  high  retention  of  FDG 
while  others  have  variable  retention  of  FDG. 
Unfortunately, FDG is not a cancer specific agent and its 
uptake has been described in a number of inflammatory 
lesions  including  sarcoidosis,  tuberculosis,  fungal 
infection,  and  cerebral  abscess.  The  increased 
accumulation is probably related to a markedly increased 
rate  of  glycolysis  within  activated  inflammatory  cells 
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[2,3,4]. Talc pleurodesis produces a visceral and parietal 
pleural  granulomatous  inflammation.  Increased  FDG 
activity has been reported in sites of pleural talc up to 
three  years  following  the  procedure,  presumably 
secondary to pleural inflammation (Figure 1) [5, 6]. 
Many potential pitfalls and artefacts associated with 
FDG PET imaging have been described. It is important 
that  we  learn  about  these  pitfalls  and  recognise  the 
important areas of normal uptake of FDG or absence of 
uptake that may be of no significance. This is necessary 
so that patients can be optimally prepared for their scans 
and accurate interpretation can be made. 
UPTAKE OF FDG IN THE HEAD AND NECK REGION 
In the brain, very intense tracer uptake occurs in the 
normal cerebral cortex and basal ganglia, glucose being 
the  predominant  substrate  for  brain  metabolism.  The 
total  uptake  in  the  brain  is  approximately  6  %  of  the 
injected dose. Normal lymphatic tissue may display low 
to moderate FDG uptake in the head and neck region. 
This is seen in the lingual and palatine tonsils and at the 
base  of  the  tongue  because  of  physiologic  activity 
associated with the lymphatic tissue in Waldeyer’s ring. 
Symmetry  is  helpful  in  evaluating  FDG  uptake  in  the 
head  and  neck.  Uptake  should  be  symmetrical  in  the 
palatine  and  lingual  tonsils.  The  soft  palate  can  also 
show tracer uptake. Variable, but typically low, uptake 
can  be  seen  in  the  salivary  glands.  The  larynx  can 
accumulate  tracer  while  the  patient  is  talking. 
Asymmetric uptake of FDG can be seen in the laryngeal 
 
Figure 1  FDG PET scan (coronal view) in a patient who had undergone pleurodesis. Increased activity is seen 
along the pleura and fissure in the right hemithorax [Image courtesy of Centre for Molecular Imaging, 
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia]. 
 
 
Figure 2  FDG PET scan (axial view) through the larynx. There is 
asymmetric  uptake  of  tracer  seen  in  the  laryngeal 
muscles while slightly more intense uptake is seen on 
the right side in this patient with left laryngeal nerve 
palsy (arrow) [Image courtesy of Centre for Molecular 
Imaging,  Peter  MacCallum  Cancer  Centre,  East 
Melbourne, Victoria, Australia]. 
 
 
 
 
Figure 3  FDG PET and fused PET CT  images (axial view) at the 
level of the thyroid gland. Focal intense uptake of tracer 
was incidentally found in the left lobe of the thyroid 
[Image courtesy of Centre for Molecular Imaging, Peter 
MacCallum Cancer Centre, East Melbourne, Victoria, 
Australia]. 
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muscles  in  patients  with  laryngeal  nerve  palsy 
contralateral  to  the  side  of  the  nerve  dysfunction  and 
should not be misinterpreted as pathologic (Figure 2). 
A  moderate  amount  of  uptake  can  be  seen  in  the 
anterior  part  of  the  floor  of  the  mouth  due  to  the 
genioglossus  muscle  which  prevents  the  tongue  from 
falling back in patients who are in the supine position. 
The cervical spinal cord  may also demonstrate  normal 
uptake, best seen in sagittal images. Diffuse symmetric 
uptake can be seen in the normal thyroid gland in about 
2%  of  scans.  Diffuse  thyroid  uptake  can  occur  in 
association  with  thyroiditis  or  Graves'  disease.  Focal 
thyroid uptake can occur with autonomously functioning 
thyroid nodules and thyroid malignancies. Patients with 
focal uptake should be further evaluated due to a higher 
risk of the result being associated with malignancy [7, 8] 
(Figure 3). 
UPTAKE OF FDG IN THE THORAX, ABDOMEN AND PELVIS 
Uptake in the thymus is commonly seen in children. 
However,  not  all  children  will  have  visible  thymic 
activity  on  FDG  PET  imaging.  The  cause  of  this 
variability in pediatric thymic accumulation of FDG is 
unclear,  but  is  likely  to  be  related  to  physical  and 
emotional stressors which influence thymic metabolism. 
In  general,  physiologic  uptake  of  FDG  in  the  thymus 
disappears in adolescence in conjunction with involution 
of the thymus. 
Rebound  thymic  hyperplasia  is  seen  in  young 
patients treated for malignancy. Following chemotherapy, 
FDG  uptake  can  be  seen  in  the  thymus  of  75%  of 
children and in 5% to 16% of adults and enlargement can 
persist  for  up  to  six  months  following  completion  of 
chemotherapy. There are several signs to ascertain non 
pathologic  thymic  FDG  accumulation.  Normal  thymic 
activity will appear triangular or “V” shaped (bilobed) 
and will usually have low to moderate uptake (Figure 4). 
Lack of uptake in the pre therapy scan should be an 
indicator  for  post  treatment  thymic  hyperplasia.  FDG 
accumulation in the thymus suggests pathology when it 
does not have a typical triangular shape or if the activity 
is very intense [9,10]. Glandular breast tissue may show 
moderate uptake of FDG and is relatively increased in 
pre menopausal  subjects  and  post menopausal  subjects 
taking hormone replacement therapy (Figure 5). Marked 
uptake may be seen in lactating breasts. 
Cardiac  activity  is  variable  ranging  from  no 
discernible activity above the background pool activity to 
intense activity throughout the left ventricle myocardium. 
It  is  unusual  to  see  atrial  or  right ventricular  activity 
unless there is cardiac disease affecting those chambers. 
In the fasting state  where insulin levels are low, FDG 
uptake  in  cardiac  muscle  should  be  low.  Myocardial 
uptake is enhanced in the presence of high blood glucose 
levels, therefore cardiac activity is marked in the post 
prandial  state.  Little  myocardial  activity  is  generally 
noted  in  the  fasting  state  as  the  myocardium 
preferentially utilises fatty acids for energy generation. 
 
 
Figure 4  FDG PET scan (coronal view) in a young adult. Normal 
thymus  is  seen  as  an  inverted  V  area  of  moderate 
uptake  (arrows)  [Image  courtesy  of  Centre  for 
Molecular  Imaging,  Peter  MacCallum  Cancer  Centre, 
East Melbourne, Victoria, Australia]. 
 
 
Figure 5  FDG PET scan (coronal view) in a young female. There 
is bilateral symmetrical moderate uptake of tracer in the 
breasts  [Image  courtesy  of  Centre  for  Molecular 
Imaging,  Peter  MacCallum  Cancer  Centre,  East 
Melbourne, Victoria, Australia]. 
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However, uptake can be variable even in the fasting state. 
We  may  see  activity  in  the  aorta  and  great  vessels, 
particularly in artherosclerotic disease. 
In  the  urinary  tract,  FDG  is  filtered  by  the 
glomerulus and is not reabsorbed by the renal tubules. So, 
significant activity may be displayed in any part of the 
urinary tract or surgical urinary diversions such as ileal 
conduits. The liver, spleen and bone  marrow  normally 
show homogenous low grade uptake. Bone marrow and 
spleen normally show less intense uptake than the liver. 
However,  in  patients  receiving  growth  colony 
stimulating factor (GCSF), increased marrow and splenic 
activity are shown on FDG PET scans (Figure 6). 
Uptake  in  the  gastrointestinal  tract  can  be  highly 
variable.  The  esophagus  does  not  usually  show 
significant  activity.  However,  the  gastroesophageal 
junction  may  show  normal  uptake.  Homogenous  low 
uptake within the stomach wall is relatively common. If 
the stomach is contracted, this  may appear as a round 
focal area of moderate activity. Small intestinal uptake is 
variable and usually of low grade. Colonic activity may 
be  quite  marked,  particularly  in  the  caecum  and 
rectosigmoid junction. In general, uptake is highest in the 
colon,  followed  by  the  small  bowel,  with  the  stomach 
showing uptake of lowest intensity. Bowel uptake can be 
diffuse but not focal.  
Testicular uptake in a male is normally seen and is 
symmetrically diffuse. However, in the female, ovarian 
uptake is not usually seen. If ovarian uptake is seen in a 
post menopausal patient, malignancy must be ruled out. 
Faint uterine activity is common. Uptake in the uterus 
has been reported during menstruation and ovulation in 
pre menopausal women and in relation to fibroids, but in 
practice it is an uncommon finding (Figure 7). 
UPTAKE OF FDG IN SOFT TISSUES 
A common area for interpretative pitfall is related to 
FDG  uptake  in  active  skeletal  muscle.  In  relaxed  and 
rested patients, no significant skeletal muscle uptake is 
noted. Muscular imbalance, e.g., post surgery, scoliosis, 
may result in increase FDG uptake in affected muscles 
(Figure 8) .Most skeletal muscle activity can easily be 
recognised as such.  
Prominent  tracer  uptake  has  also  been  described 
within  the  supraclavicular  fat  on  FDG  PET  scans  in 
about 2% to 4% of patients. The aetiology is not well 
understood, but is felt to be related to the presence of 
"brown fat" (brown adipose tissue). Brown fat is most 
prominent in newborns and diminishes with age. Unlike 
white adipose tissue it has the capacity to generate heat. 
It is stimulated by several factors, including exposure to 
cold. The incidence of tracer uptake in brown fat also 
increases  in  women.  Areas  in  which  prominent  tracer 
uptake into brown fat is seen are in the supraclavicular 
regions followed by the axillae, mediastinum, intercostal, 
paravertebral, and perinephric regions (Figure 9). Even 
 
 
 
Figure 6  FDG  PET  scan  (coronal  view)  in  a  patient  who  had 
received  growth  colony  stimulating  factor  (GCSF). 
There is increased marrow activity seen in the spine and 
pelvis and increased splenic activity [Image courtesy of 
Centre  for  Molecular  Imaging,  Peter  MacCallum 
Cancer Centre, East Melbourne, Victoria, Australia]. 
 
 
 
 
Figure 7  FDG PET CT scan (axial view) of the pelvis. Activity is 
seen in the endometrial cavity in this patient who was 
menstruating (arrow). On the fused image, the uterus is 
seen  to  be  retroverted  [Image  courtesy  of  Centre  for 
Molecular  Imaging,  Peter  MacCallum  Cancer  Centre, 
East Melbourne, Victoria, Australia]. 
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Figure 8  FDG  PET  scan  (coronal  view).There  is  increased  activity  seen  in  the  neck  and  shoulder  muscles. 
Moderate uptake is also seen in the psoas muscles in this patient with scoliosis (arrows) [Image courtesy 
of  Centre  for  Molecular  Imaging,  Peter  MacCallum  Cancer  Centre,  East  Melbourne,  Victoria, 
Australia]. 
 
 
 
         
Figure 9  FDG PET scan (coronal view). Intense tracer uptake is seen into brown fat seen in the supraclavicular, 
intercostal  and  paravertebral  regions  [Image  courtesy  of  Centre  for  Molecular  Imaging,  Peter 
MacCallum Cancer Centre, East Melbourne, Victoria, Australia]. 
 
 
 
       
Figure 10 From left to right   axial CT image, PET image and fused PET CT image at the same level showing 
areas of intense uptake fat in the supraclavicular regions (arrows). The PET/CT fused images facilitated 
differentiation between fat and pathological tissue [Image courtesy of Centre for Molecular Imaging, 
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia]. 
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when  recognised  as  a  benign  variant,  the  degree  of 
uptake can easily obscure malignant lymphadenopathy in 
the  region.  With  PET CT  imaging  it  is  now  easier  to 
differentiate fat and pathological tissue (Figure 10) [11]. 
It is essential to be aware of the clinical correlation 
of other sites of uptake or absence of uptake that may be 
of no significance. These include healing fractures (less 
than  three  months)  and  healing  surgical  incision  sites, 
sites of previous radiation therapy (no or low  uptake), 
joint prosthesis (not infected), degenerative joint disease, 
stoma sites (colostomy, ileostomy, tracheostomy), chest 
tube drainage site, biopsy sites and porta cath sites. 
PATIENT PREPARATION AND OTHER TECHNICAL ISSUES 
Adequate  patient  preparation  is  necessary  to 
minimise the appearance of potential artefactual uptake 
patterns  that  make  interpretation  difficult.  Exercise 
should  be  avoided  on  the  day  of  scanning  to  avoid 
muscle  uptake. Patients  need to be totally relaxed and 
kept warm. If the patient is cold and nervous, clenching 
their hands will increase muscle activity in the forearms, 
resulting  in  increased  tracer  uptake.  Stress induced 
muscle  tension  is  often  seen  in  the  trapezius  and 
paraspinal muscles. Those known to have muscle spasms 
may  be  administered  benzodiazepines  before  the  FDG 
injection.  This  minimises  uptake  by  normal  skeletal 
muscles, particularly the proximal muscles, which would 
make neck and supraclavicular nodal evaluation difficult. 
Patients  are  advised  to  avoid  talking,  chewing  and 
swallowing too much to reduce accumulation of tracer 
into  muscles of  mastication  and the  larynx. Brown  fat 
has the capacity to generate heat. It is known to increase 
glucose uptake when the sympathetic nervous system is 
activated  by  cold  stimulation.  Therefore,  keeping  the 
patient  warm  may  be  helpful  in  reducing  uptake  into 
brown fat. 
Patients are prepared for PET CT scans in the same 
manner as for PET scanning. The CT scan is done before 
the PET scan. For oncological indications, an extended 
body  survey  is  usually  acquired,  typically  including 
images from the skull base to the proximal thighs. The 
typical acquisition time is less than a minute for the CT 
scan. The CT component is performed as a non contrast 
low  radiation  dose  scan.  It  is  performed  primarily  for 
attenuation correction and anatomical correlation. Next, 
without the patient moving or changing position, a PET 
scan encompassing the same imaging field is performed. 
The  resulting  PET CT  studies  are  interpreted  at  a 
computer workstation with dedicated software allowing 
review  of  attenuation  corrected  PET,  CT  and  fusion 
PET CT images in three orthogonal planes. Both the CT 
and  PET CT  fusion  images  are  used  to  localise  PET 
uptake abnormalities. Many of the problems with regard 
to pitfalls and areas of normal uptake described above 
are  solved  with  the  use  of  PET CT  imaging.  PET CT 
imaging will reduce diagnostic uncertainty with respect 
to  physiologic  activity  by  allowing  more  confident 
interpretation  related  to  areas  of  anatomically  normal 
structures. It merges anatomic and molecular data with 
the aim of producing one integrated diagnosis. 
Development  of  the  combined  PET CT  scanners 
comes  with  its  own  specific  problems  related  to  the 
combined  PET CT  technique  [8].  Differences  in 
breathing  patterns  between  the  CT  and  the  PET  scans 
may  lead  to  misregistration,  e.g.,  a  pulmonary  nodule 
situated in the periphery and in the bases of the lungs. 
Misregistration may be minimised by performing the CT 
during  expiration  instead  of  inspiration.  High  density 
substances, e.g., contrast agents or metallic objects, can 
lead to artefactual overestimation of activity if CT data 
are used for attenuation correction. The artefacts can be 
recognised by studying the uncorrected image data. Use 
of  intravenous  contrast  during  the  CT  acquisition  may 
lead  to  over correction  of  attenuation  artefactual  hot 
areas in the attenuation corrected image and quantitative 
over estimation  of  FDG  activity/uptake.  A  separate 
contrast enhanced CT examination is indicated if use of 
intravenous  contrast  is  essential  to  increase  diagnostic 
accuracy. 
In summary;  
●  FDG will localise to any part of the body where 
there is high physiologic activity. 
●  Basic  to  the  proper  interpretation  of  PET CT 
scans  is  a  clear  understanding  of  the  normal 
variants of uptake and awareness of the benign 
processes that are FDG avid to avoid potential 
pitfalls in image interpretation. 
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